Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nano-org, a functional resource for single-molecule localisation microscopy data.

Nature communications·2025
Same author

Expert consensus on neurodevelopmental outcomes in pregnancy pharmacovigilance studies.

Frontiers in pharmacology·2023
Same author

Cognitive disorders in epilepsy II: Clinical targets, indications and selection of test instruments.

Seizure·2020
Same author

Sleep Quality in Children and Adults with Rett Syndrome.

Neuropediatrics·2020
Same author

Cessation of gamma activity in the dorsomedial nucleus associated with loss of consciousness during focal seizures.

Epilepsy & behavior : E&B·2015
Same author

Intraperitoneal and subcutaneous injections of the TLR9 agonist ODN 1668 in rats: brain inflammatory responses are related to peripheral IL-6 rather than interferons.

Journal of neuroimmunology·2014

Related Experiment Videos

Topiramate dose effects on cognition: a randomized double-blind study.

D W Loring1, D J Williamson, K J Meador

  • 1Department of Neurology, Emory University, 101 Woodruff Circle, Suite 6000, Atlanta, GA 30322, USA. dloring@emory.edu

Neurology
|December 15, 2010
PubMed
Summary
This summary is machine-generated.

Topiramate (TPM) can cause dose-dependent cognitive impairment. Early cognitive changes at 6 weeks predict later impairment, allowing for early identification of at-risk individuals.

Related Experiment Videos

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Psychology

Background:

  • Topiramate (TPM) is a broad-spectrum antiepileptic drug.
  • TPM has been linked to neuropsychological impairment in epilepsy patients and healthy individuals.

Purpose of the Study:

  • To determine if TPM-induced neuropsychological impairment is dose-dependent.
  • To assess if early cognitive response predicts later outcomes.

Main Methods:

  • 188 healthy adults received placebo or TPM (64-384 mg/day) for 24 weeks.
  • Computerized neuropsychological tests were administered at baseline and 6, 12, and 24 weeks.
  • Reliable Change Index (RCI) analysis quantified individual cognitive changes.

Main Results:

  • Neuropsychological effects were dose-dependent (p < 0.0001).
  • Higher TPM doses led to increased neuropsychological decline (35% at 384 mg vs. 5% placebo).
  • 6-week cognitive changes predicted 24-week outcomes.

Conclusions:

  • TPM-induced neuropsychological impairment is dose-dependent.
  • Early identification of at-risk individuals is possible within 6 weeks of treatment.
  • RCI analysis effectively quantifies individual neuropsychological risk.